Fzata, Inc.
Wednesday, June 05, 2024
Start-Up Stadium Session
![Platform for Therapeutics](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
5B
Company Description: Fzata (fzata.com) has solved the oral biologics problem with the BIoPYM platform. Live yeast micro-factories make and secrete biologic therapeutic in the GI. Direct GI targeting avoids anti-drug antibody and systemic tox common to biologics like Humira which suffer upto a 50% discontinuation rate. We are an NIH Seed company with $17M non-dilutive. First in human clinical study will be 2024 for FZ002 c diff program fully supported by NIH. We are now raising seed $10M to support FZ006 IBD program. FZ006 will be the first oral anti-TNFalpha for IBD and also the first anti-TNFalpha for the mild-moderate IBD population. This is a multi-billion dollar market in the US alone and a huge unmet medical need.
![Fzata, Inc.](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1737771-1-JPG.png)
Company Website:
http://www.fzata.com
Company HQ City
Halethorpe
Company HQ State
Maryland
Company HQ Country
United States
CEO/Top Company Official
Zhiyong Yang, CEO
Primary Speaker